Insights Hub
Latest Insights / Blog Articles
Topic Filters
Leader note: Pick a track and I’ll connect each post to the most relevant service and case study so you can see the real-world application.
The 8 events pharma must govern
Next step: Ship the consent param schema and reconcile BI↔platform within ±2%.
Copilots that pass MLR (prompts + audit pack)
Next step: Add audit logging + service levels to your SOWs.
Claims libraries, fair-balance patterns, pre-flight by channel . Next step: Adopt the redline loop + evidence map before your next review.
DTC Reality 2025: What the White House/FDA crackdown means for marketers
The Sept 9, 2025 Presidential Memorandum directed HHS/FDA to rein in misleading Rx ads; FDA followed with mass warnings/cease-and-desists and signaled tighter risk disclosure in broadcast and social—expect stricter “fair balance” enforcement and faster letters. Politico; The White House; U.S. Food and Drug Administration
Next step: Re-audit all DTC copy (TV/CTV, social, creator, podcasts) for major-statement/ISI sufficiency; update your reviewer packet and short-form patterns; document policy acceptance tests in SOWs.
The Cookieless Reality Check: What’s next for CMOs—and how to win anyway
Chrome’s 2025 posture: third-party cookies remain available while Privacy Sandbox APIs roll out; the pivot still pressures consent, first-party data, and modeled measurement—don’t pause migrations, just refocus them. Privacy Sandbox
Next step: Ship your consent-mode schema, first-party data plan, and sandbox tests (attribution/reporting) with a BI reconciliation rulebook.
Leader note: Pick a track and I’ll connect each post to the most relevant service and case study so you can see the real-world application.
The 8 events pharma must govern
Next step: Ship the consent param schema and reconcile BI↔platform within ±2%.
Claims libraries, fair-balance patterns, pre-flight by channel . Next step: Adopt the redline loop + evidence map before your next review.
DTC Reality 2025: What the White House/FDA crackdown means for marketers
The Sept 9, 2025 Presidential Memorandum directed HHS/FDA to rein in misleading Rx ads; FDA followed with mass warnings/cease-and-desists and signaled tighter risk disclosure in broadcast and social—expect stricter “fair balance” enforcement and faster letters. Politico; The White House; U.S. Food and Drug Administration
Next step: Re-audit all DTC copy (TV/CTV, social, creator, podcasts) for major-statement/ISI sufficiency; update your reviewer packet and short-form patterns; document policy acceptance tests in SOWs.
The Cookieless Reality Check: What’s next for CMOs—and how to win anyway
Chrome’s 2025 posture: third-party cookies remain available while Privacy Sandbox APIs roll out; the pivot still pressures consent, first-party data, and modeled measurement—don’t pause migrations, just refocus them. Privacy Sandbox
Next step: Ship your consent-mode schema, first-party data plan, and sandbox tests (attribution/reporting) with a BI reconciliation rulebook.
For pharma leaders seeking on-label growth
MLR-safe, strategy-led, data-driven—powering blockbuster optimization from GTM to new-indication lift-offs. I publish evidence-based articles, guidance, and working templates so your teams can move quickly and effectively without risking OPDP/APLB, HIPAA, or GDPR.
Subscribe to the Omnichannel Transformation Digest
Get the Governance Playbook
Webinars / Events
Upcoming masterclass
Build a KPI Layer Your Regions Trust (in 30 Days)
What you’ll get:
- KPI dictionary template
- Stitching map
- Decision One-Pager
On-demand library
Cookie Deprecation: consent-first analytics that still measure outcomes
AI in Paid Pharma: prompts, risks, and the audit trail
Journey QA: pre-flight to post-flight with OPDP checks